

**COUNCIL OF THE DISTRICT OF COLUMBIA
COMMITTEE ON HEALTH
NOTICE OF PUBLIC HEARING
1350 PENNSYLVANIA AVE., N.W., WASHINGTON, D.C. 20004**

**COUNCILMEMBER VINCENT C. GRAY, CHAIRPERSON
THE COMMITTEE ON HEALTH**

ANNOUNCES A PUBLIC HEARING ON

**BILL 22-0196, "ACCESS TO TREATMENT FOR ANAPHYLAXIS AMENDMENT ACT
OF 2017"**

BILL 22-0228, "SAFE DISPOSAL OF PHARMACEUTICALS AMENDMENT ACT OF 2017"

**BILL 22-0333, "ADVANCED PRACTICE REGISTERED NURSE SIGNATURE
AUTHORITY AMENDMENT ACT OF 2017"**

**BILL 22-0350, "HOME VISITING SERVICES PILOT PROGRAM ESTABLISHMENT
ACT OF 2017"**

BILL 22-0399, "INFANT MORTALITY REDUCTION PROGRAM ACT OF 2017"

**MONDAY, SEPTEMBER 18, 2017
11 A.M., ROOM 500, JOHN A. WILSON BUILDING
1350 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, D.C. 20004**

Councilmember Vincent C. Gray, Chairperson of the Committee on Health, announces a Public Hearing on the Bill 22-0196, the "Access to Treatment for Anaphylaxis Amendment Act of 2017", Bill 22-0228, the "Safe Disposal of Pharmaceuticals Amendment Act of 2017", Bill 22-0333, the "Advanced Practice Registered Nurse Signature Authority Amendment Act of 2017", Bill 22-0350, the "Home Visiting Services Pilot Program Establishment Act of 2017", and Bill 22-0399, the "Infant Mortality Reduction Program Act of 2017." The hearing will be held on Monday, September 18, 2017, at 11a.m., in Room 500 of the John A. Wilson Building.

Bill 22-0196, the "Access to Treatment for Anaphylaxis Amendment Act of 2017" establishes what entities are authorized to administer an epinephrine auto-injector to individuals experiencing anaphylaxis and allows licensed physicians to prescribe the epinephrine auto-injectors to authorized entities. Agents of the authorized entities must be acting in good faith and must have completed a training program conducted by a nationally recognized organization experienced in training laypersons in emergency health treatment. It also provides immunity from civil and criminal liability to health care professionals who prescribe and agents of an authorized entity who provide or administer an epinephrine auto-injector.

Bill 22-0228, the “Safe Disposal of Pharmaceuticals Amendment Act of 2017” requires that the Department of Health install drop boxes for the disposal of expired or unused controlled substances at law enforcement agencies, retail pharmacies and hospitals with an on-site pharmacy. It also identifies which controlled substances a person may voluntarily surrender without identifying themselves.

Bill 22-0333, the “Advanced Practice Registered Nurse Signature Authority Amendment Act of 2017” enables advanced practice registered nurses to sign, certify, stamp, or endorse all documents related to healthcare within their scope of practice.

Bill 22-0350, the “Home Visiting Services Pilot Program Establishment Act of 2017” requires that the Deputy Mayor for Health and Human Services conduct a feasibility study to assess the ability of a pay-for-success model to improve, expand, and sustain home visiting programs. It also establishes a special fund which shall be used to award grants and make payments due in accordance with pay-for-success contracts. Among other things, it requires annual reporting on home visiting services and it establishes the Help Me Grow program District-wide.

Bill 22-0399, the “Infant Mortality Reduction Program Act of 2017” establishes a baby box program to distribute baby boxes at the birth of a child at no-cost to parents to reduce infant mortality in the District, provides education and training on safe sleeping arrangements for infants, provides baby boxes to foster youth with infants, and requires DOH to report on the outcomes of the baby box program on infant mortality.

The Committee invites the public to testify at the hearing. Those who wish to testify should contact Malcolm Cameron, Committee Legislative Analyst at (202) 654-6179 or mcameron@dccouncil.us, and provide your name, organizational affiliation (if any), and title with the organization, preferably by 5:00 p.m. on Thursday, September 14, 2017.

Witnesses should bring 15 copies of their written testimony to the hearing. The Committee allows individuals 3 minutes to provide oral testimony in order to permit each witness an opportunity to be heard. Additional written statements are encouraged and will be made part of the official record. Written statements may be submitted by e-mail to mcameron@dccouncil.us or mailed to: Council of the District of Columbia, 1350 Pennsylvania Ave., N.W., Suite 113, Washington D.C. 20004.

2017 JUL 28 AM 10:55

OFFICE OF THE
SECRETARY